Drug companies credit rating is about to be issued, with gold sales, price monopoly will be severely be severely beaten.

Pharmaceutical Network Industry Dynamics Recently, the website of the State Administration of Health Insurance officially listed the "Guidance on the Establishment of Drug Price sandin rating system (draft for comments)" for public comments.it is understood that the policy relies on pharmaceutical and medical supplies tender procurement platform, system integration and trustworthiness commitment, credit rating, graded disposal, credit repair and other mechanisms, the establishment of equal rights and responsibilities, coordination of linked pharmaceutical prices and credit evaluation system.aimed at obtaining improper benefits through the breach of trust listed in the catalogue list in the process of pricing, bidding, performance and marketing shall be included in the scope of pharmaceutical prices and credit recruitment evaluation.it is worth noting that from the time the opinion was issued, this document has been in force, that is, from July 24, all pharmaceutical companies, there are bribes, kickbacks, false VAT invoices and other acts of breach of trust, will be included in the scope of pharmaceutical prices and credit evaluation.in fact, the pharmaceutical industry with gold sales and other persistent diseases have a long history, before there are many medical institutions or their staff because of the "kickback" by the media and public attention.in the eyes of the industry, the pharmaceutical field of breach of trust behavior is long-term existence, to a large extent because of the lack of institutional constraints, the cost of breach of trust is too low, the punishment of breach of trust is not in place.Although over the years, different departments have adopted various strategies for the sale of pharmaceutical companies, but either the punishment is difficult to enforce, or the punishment is relatively light, most of the impact is limited.But in recent years this situation has begun to change significantly, with medical reform into the deep water area, the field of pharmaceutical purchase and sale of anti-corruption has become the implementation of various policies of the "transportation hub."since 2018, the National Health and Care Commission, the State Health Insurance Administration and other nine ministries jointly issued the "2018 to correct the pharmaceutical purchase and sale of the field and medical services in the field of the special governance of the main points of the work," provinces and cities have also issued anti-corruption documents for the purchase and sale of medicines, anti-corruption and high-pressure continued.especially since 2019, from the Ministry of Finance, the Health Insurance Bureau to 77 pharmaceutical companies to carry out fiscal and tax verification storm, access to drug companies first-hand cost structure information;industry believes that the draft will further curb pharmaceutical companies with gold sales, price monopoly and other irregularities.in general, under the general trend of drug reform, whether it is the financial verification of 77 pharmaceutical companies, or the establishment of marketing and price behavior credit rating, one of its purposes is to provide reference for drug collection and collection work.for pharmaceutical companies, multi-directional, multi-angle to look at their own marketing and price behavior is imminent, and after this, accelerate the transformation of marketing compliance will become all pharmaceutical companies urgently need to solve the big problem..